Anti-Human HLA A2,B7 (MHC Class I) [Clone BB7.6] — Purified in vivo GOLD™ Functional Grade
Anti-Human HLA A2,B7 (MHC Class I) [Clone BB7.6] — Purified in vivo GOLD™ Functional Grade
Product No.: H1685
Clone BB7.6 Target HLA-A2,B7 MHC Class I Formats AvailableView All Product Type Monoclonal Antibody Alternate Names HLA-A, HLA-A2,B7, B.C.HLA-A2 Isotype Mouse IgG1 Applications FC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen Solubilized HLA-B7 antigen Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893725 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone BB7.6 recognizes an epitope shared by the human MHC class I molecule HLA-B.
Background HLA-B antibody, clone BB7.6, recognizes a shared epitope (Bw6) of the major histocompatibility complex (MHC) class I molecule human leukocyte antigen (HLA)-B1. MHC class I is ubiquitously expressed on the cell surface of nucleated cells and consists of a 45-kDa type I transmembrane glycoprotein (α-chain or heavy chain) and a 12-kDa soluble protein (β2-microglobulin, β2M)2,3. The α-chain consists of three domains (α1, α2, and α3)4. α1 and α2 form the closed antigen-binding groove and bind to 8-10 aa peptides derived from cytosolic antigens5-7. β2M noncovalently associates with α3, which is essential for MHC stability. MHC class I plays a critical role in the adaptive immune response by presenting endogenous antigens to cytotoxic CD8 T cells. MHC class I molecules can also present exogenous antigens to CD8 T cells via a process known as cross-presentation8. The T cell receptor (TCR)/CD3 complex of CD8 T cells interacts with peptide-MHC class I, which induces CD8 T cell activation and subsequent cell-killing. CD8 molecules also bind to MHC class I, which helps augment TCR signaling9. In contrast to CD8 T cells, MHC class I is an inhibitory ligand for natural killer (NK) cells, promoting self tolerance10. MHC class I also contributes to the positive selection of CD8 T cells and NK cell specificity11,12.
Antigen Distribution HLA-B is ubiquitously expressed on nucleated cells.
Research Area Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone BB7.6 is a mouse monoclonal antibody targeting the human MHC class I molecules HLA-A2 and HLA-B7, and it is formulated for use in in vivo studies in mice, primarily to modulate, deplete, or track human MHC class I-expressing cells in xenograft or humanized mouse models.
Summary Table: Usage of BB7.6 in In Vivo Mouse Studies
BB7.6 is not used for targeting mouse H-2 MHC molecules, but specifically recognizes human HLA class I antigens, making it valuable in studies requiring discrimination between mouse and human immune components. Always consult product-specific datasheets and protocols for detailed handling instructions. Commonly used antibodies or proteins in the literature with BB7.6 (an anti-Bw6 monoclonal antibody targeting specific HLA class I epitopes) include other antibodies directed against Bw4 and Bw6 epitopes, such as SFR8-B6 (anti-Bw6), and a collection of both mouse and human monoclonal antibodies recognizing Bw4 and Bw6 variants. Essential context:
Additional relevant antibodies and proteins commonly used in combination research:
In cancer immunotherapy or diagnostic contexts, antibodies such as anti-PD-1 are sometimes combined with other specific antibodies (e.g., in bispecific formats or sequential treatments), but this is less typical for BB7.6, whose primary use is in HLA specificity mapping rather than direct clinical therapy. Summary: Antibodies/proteins most frequently paired or compared with BB7.6
Clone BB7.6 is a monoclonal antibody used extensively in scientific literature to characterize HLA class I Bw6 epitopes and analyze their molecular structure and antibody interactions. Key findings from citations referencing clone BB7.6 include:
In summary, clone BB7.6 is instrumental in defining the molecular details of the HLA-Bw6 epitope and in advancing our understanding of HLA diversity, antibody specificity, and NK cell interactions in the context of immunity and transplantation. There is insufficient direct published data specifically detailing how dosing regimens of clone BB7.6 (an anti-HLA-A2 monoclonal antibody) vary across different mouse models in the search results provided. Standardized antibody dosing regimens in murine studies typically depend on several factors, including:
General patterns for antibody dosing in mouse models:
Variability across mouse models:
For BB7.6 specifically: Summary table: General Antibody Dosing in Mouse Models
Key considerations:
In sum: References & Citations1. Lutz CT, et al. (1994) J Immunol. 153(9):4099-110. 2. Mitaksov V & Fremont DH. (2006) J Biol Chem. 281(15):10618-25. 3. Wieczorek M, et al. (2017) Front Immunol. 8:292. 4. Jones EY. (1997) Curr Opin Immunol. 9(1):75-9. 5. Matsumura M, et al (1992) Science. 257:927–34.10.1126/science.1323878 6. Bouvier M & Wiley DC. (1994) Science. 398–402.10.1126/science.8023162 7. Zacharias M & Springer S. (2004) Biophys J. 87:2203–14.10.1529/biophysj.104.044743 8. Cruz FM, et al. (2017) Annu Rev Immunol. 35:149-176. 9. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921. 10. Orr MT & Lanier LL. (2010) Cell. 142(6):847-856. 11. Raulet DH. (1994) Adv Immunol. 55:381-421. 12. Salcedo M & Ljunggren HG. (1996) Chem Immunol. 64:44-58. Technical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
---|---|
S211 | |
R1364 | |
I-117 | |
I-536 | |
F1175 |
Formats Available
